Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice

Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2016-08, Vol.236, p.15-21
Main Authors: van Wamel, Annemieke, Sontum, Per Christian, Healey, Andrew, Kvåle, Svein, Bush, Nigel, Bamber, Jeffrey, de Lange Davies, Catharina
Format: Article
Language:English
Subjects:
Abraxane
Acoustic cluster therapy
Act
Albumin-Bound Paclitaxel - administration & dosage
Animals
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Cell Line, Tumor
Drug Delivery Systems
Drug Liberation
Humans
Male
Mice
Paclitaxel
Paclitaxel - administration & dosage
PC-3 prostate adenocarcinoma
Pre-clinical
Prostatic Neoplasms - drug therapy
Targeted drug delivery
Ultrasonic Waves
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous human prostate adenocarcinoma (PC3) in mice. In combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic efficacy; 120days after study start, 42% of the animals were in stable, complete remission vs. 0% for the paclitaxel only group and the median survival was increased by 86%. In combination with Abraxane® (12mg paclitaxel/kg given i.v.), ACT induced a strong increase in the therapeutic efficacy; 60days after study start 100% of the animals were in stable, remission vs. 0% for the Abraxane® only group, 120days after study start 67% of the animals were in stable, complete remission vs. 0% for the Abraxane® only group. For the ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane® only group. Proof of concept for Acoustic Cluster Therapy has been demonstrated; ACT markedly increases the therapeutic efficacy of both paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2016.06.018